Clinical Trial Update: Hypofractionated, Dose Escalation Radiotherapy for High Risk Adenocarcinoma of the Prostate [Phase 3]

View source ↗

Summary

An update on a Phase 3 trial evaluating hypofractionated, dose-escalation radiotherapy for high-risk prostate cancer, currently listed as Active Not Recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Snippet

Sponsor: Sir Mortimer B. Davis - Jewish General Hospital | Conditions: Prostate Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING